XOMA Highlights Royalty Aggregation Strategy in Updated Presentation

XOMA Royalty Corporation ( (XOMA) ) has provided an update.

On March 2, 2026, XOMA Royalty Corporation released an updated corporate presentation that highlights its differentiated position as a biotech royalty aggregator focused on smaller, early- to mid-stage clinical assets. The presentation underscores its compounding model of growing royalty cash receipts, maintaining low expenses and share count, and using creative deal-making to add more than 100 assets with over $140 million in milestones received since 2017 and more than $2 billion in potential future milestones.

The materials review 2025 activity, including multiple royalty and royalty-plus-acquisition deals, the sale of all pipeline assets, and a share repurchase program that retired 648,048 shares for $16 million, as well as Section 174 tax benefits that supported non-dilutive capital deployment. XOMA also provides preliminary 2025 figures showing $49–50 million in royalty and milestone cash receipts, about $133 million in cash and restricted cash at year-end, an enterprise value of roughly $449–549 million, and notes higher G&A expenses from ongoing litigation against Janssen Biotech over alleged unauthorized use of its intellectual property in TREMFYA, signaling both legal risk and potential upside for stakeholders.

The most recent analyst rating on (XOMA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on XOMA Royalty Corporation stock, see the XOMA Stock Forecast page.

Spark’s Take on XOMA Stock

According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.

Overall score reflects mixed financial performance (strong margins but elevated leverage and weak cash-flow trends) as the primary driver, with neutral technical signals and a high P/E weighing on the outlook; positive corporate developments provide a modest offset.

To see Spark’s full report on XOMA stock, click here.

More about XOMA Royalty Corporation

XOMA Royalty Corporation is a biotech-focused royalty aggregator that acquires milestone and royalty interests in early- to mid-stage clinical and commercial drug assets. Listed on Nasdaq with both common and perpetual preferred shares, the company targets smaller, often non-dilutive royalty transactions and aims to build a diversified portfolio that generates stable, growing cash flows with relatively low operating expenses and a lean share count.

The company concentrates on royalty streams from therapies across multiple indications, including pulmonary arterial hypertension, hyperinsulinism, liver and gastrointestinal diseases, oncology and women’s health. Its model is designed to compound value over time by increasing the number of royalty assets, capturing milestone payments, and returning excess capital to shareholders through buybacks while maintaining financial flexibility through cash reserves and royalty-backed debt.

Average Trading Volume: 403,542

Technical Sentiment Signal: Sell

Current Market Cap: $316.1M

Find detailed analytics on XOMA stock on TipRanks’ Stock Analysis page.